Lu177-PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution.

Lutetium-177-PSMA (LuPSMA) is a targeted systemic radioligand treatment for metastatic castration-resistant prostate cancer (mCRPC). LuPSMA is considered as an experimental treatment not yet used in routine practice.